Anebulo Pharmaceuticals (ANEB) AI Stock Analysis

• Market Cap: $48.89M
• Dividend Yield: N/A
• Average Volume (3M): 16.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: 23.10%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 41,084,732
• 10 Day Avg. Volume: 7,376
• 30 Day Avg. Volume: 16,982
• PEG Ratio: 0.26
• Price to Book (P/B): 4.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.67
• Enterprise Value/Market Cap: 1.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -11.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.96 ▼(-14.02% Downside)

The score is primarily weighed down by weak financial fundamentals (no revenue, ongoing losses and cash burn) and bearish technicals (price far below major moving averages with negative MACD). Valuation is constrained by the lack of earnings and no dividend, and the going-private/delisting-related event adds additional uncertainty.

Positive Factors

Strong Balance Sheet

A strong balance sheet with zero debt provides financial stability and flexibility, allowing Anebulo to focus on R&D and strategic initiatives without the burden of interest payments.

Focus on Unmet Medical Needs

Targeting unmet medical needs in the growing cannabinoid market positions Anebulo to potentially capture significant market share if their treatments prove effective and gain regulatory approval.

Potential Revenue Streams

Future licensing agreements and strategic partnerships can provide substantial revenue and funding, supporting long-term growth and reducing reliance on equity financing.

Negative Factors

Lack of Revenue Generation

The absence of revenue generation and ongoing losses highlight operational inefficiencies and the challenge of achieving profitability, which is critical for long-term sustainability.

Heavy Reliance on Financing

Dependence on external financing poses a risk if funding sources diminish, potentially impacting the company's ability to continue operations and invest in R&D.

Negative Cash Flow

Negative cash flow indicates that the company is spending more than it earns, which can strain financial resources and necessitate further financing, affecting long-term viability.

Anebulo Pharmaceuticals Business Overview & Revenue Model

Company Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

How the Company Makes Money

Anebulo Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, ANEB-001. As a clinical-stage company, Anebulo's current revenue streams are limited, and it largely relies on funding through public and private investment to support its research and development activities. In the future, the company plans to earn income through licensing agreements, strategic partnerships, and sales of its pharmaceutical products upon receiving regulatory approval. Significant partnerships with larger pharmaceutical companies could also contribute to its revenue by providing milestone payments, royalties, and collaborative research funding.

Anebulo Pharmaceuticals Financial Statement Overview

Summary

Anebulo Pharmaceuticals faces significant financial challenges typical of early-stage biotech companies. With no revenue and consistent losses, the company relies heavily on equity financing to sustain its operations. While the balance sheet is strong due to zero debt, the ongoing cash burn and lack of profitability are major concerns. Investors should be cautious and consider the company's ability to secure future funding and achieve revenue growth.

Income Statement

Anebulo Pharmaceuticals has shown consistent net losses over the years, with no revenue generation. The TTM data shows a net income of -$7.67 million, indicating a lack of profitability. The absence of revenue growth and negative EBIT and EBITDA margins highlight the company's struggle to achieve operational efficiency.

Balance Sheet

The company maintains a strong equity base with zero debt, leading to a favorable debt-to-equity ratio. However, the return on equity remains negative due to continuous losses. The equity ratio is high, indicating reliance on equity for funding, which is common in early-stage biotech firms.

Cash Flow

Anebulo has a negative free cash flow, with the TTM free cash flow being -$6.65 million. The operating cash flow to net income ratio is relatively stable, but the company relies heavily on financing activities to sustain operations. This reliance poses a risk if external funding sources dry up.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.10M	-8.10M	-7.79M	-11.73M	-6.83M	-30.24M
Net Income	-8.44M	-8.48M	-8.20M	-11.73M	-6.83M	-30.25M
Balance Sheet
Total Assets	10.70M	12.15M	4.07M	11.67M	15.58M	21.65M
Cash, Cash Equivalents and Short-Term Investments	10.35M	11.63M	3.09M	11.25M	14.55M	19.99M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	963.82K	487.69K	260.58K	1.07M	512.53K	241.63K
Stockholders Equity	9.74M	11.66M	3.81M	10.60M	15.07M	21.41M
Cash Flow
Free Cash Flow	-5.93M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Operating Cash Flow	-5.93M	-6.35M	-8.09M	-9.68M	-5.44M	-4.87M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	14.88M	14.88M	-62.35K	6.38M	0.00	21.83M

Anebulo Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 1.12 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 2.08, and below the 200-day MA of 1.90, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 29.77 is Positive, neither overbought nor oversold. The STOCH value of 67.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.

Anebulo Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNTX	56 Neutral	$147.01M	-5.72	-33.68%	―	―	69.30%
ANRO	56 Neutral	$493.64M	-6.90	-45.01%	―	―	-7.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$163.37M	-0.87	―	―	-63.96%	-28.50%
VTGN	46 Neutral	$27.80M	-0.44	―	―	-33.00%	54.91%
ANEB	44 Neutral	$48.89M	-5.06	-145.11%	―	―	23.10%
BYSI	43 Neutral	$65.38M	―	―	―	―	―

Anebulo Pharmaceuticals Corporate Events

Anebulo Pharmaceuticals Launches Self-Tender Offer to Go Private

On December 22, 2025, Anebulo Pharmaceuticals announced that its board had abandoned a previously proposed large reverse stock split and related special shareholder meeting in favor of launching a voluntary self-tender offer as part of its plan to go private. The company intends to commence a cash tender offer to buy up to 300,000 shares of its common stock at $3.50 per share, for a total of up to $1.05 million, a move aimed at keeping its shareholder count below 300, the threshold needed to complete its going-private transaction. The board concluded that the reverse split had become too costly after certain investors distributed holdings across multiple small accounts to maximize fractional share payouts, significantly increasing the projected expense of that strategy. By shifting to the self-tender approach, Anebulo is seeking a more economically efficient path to delisting and deregistration while retaining the option to revisit a reverse split or other structural transaction in the future if conditions change.

The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.